Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

BACKGROUND: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Forbes, John F, Sestak, Ivana, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael, Holcombe, Chris, Coleman, Robert E, Jones, Louise, Ellis, Ian, Cuzick, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769326/
https://www.ncbi.nlm.nih.gov/pubmed/26686313
http://dx.doi.org/10.1016/S0140-6736(15)01129-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769326/
https://www.ncbi.nlm.nih.gov/pubmed/26686313
http://dx.doi.org/10.1016/S0140-6736(15)01129-0

Ejemplares similares